Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy
Journal
Urological Research
Journal Volume
41
Journal Issue
3
Pages
247-252
Date Issued
2013
Author(s)
Abstract
The objective of this study is to evaluate the effects of solifenacin on double-J stent-related symptoms following uncomplicated ureterosocpic lithotripsy (URSL). A total of 70 patients who underwent double-J ureteral stent insertion following URSL were consecutively recruited and received solifenacin postoperatively. Another 70 age- and sex-matched subjects without solifenacin therapy were enrolled as a control group. The clinical data including stone and stent characteristics were collected. All subjects completed the brief-form Ureteral Symptom Score Questionnaire (Chinese-version) to assess the lower urinary tract symptoms, stent-related body pain and hematuria 2 weeks after operation. The severity of stent-related symptoms was compared between two groups. The mean age was 53.8 in solifenacin group and 53.4 years in the control group (p = 0.87). The stone characteristics, stent size, position and curl completeness were similar in both groups. Compared to the control group, solifenacin group had significantly lower total symptom score, urgency and urge incontinence scores. As for stent-related body pain, solifenacin group had significantly less flank, abdominal, urethral pain and hematuria scores (all p<0.05). The solifenacin versus control group showed significant benefits in lower urinary tract symptoms, stent-related pain and hematuria in both genders (all p<0.05). Four subjects encountered minor adverse events (5.7 %) and one had urinary retention (1.4 %) in solifenacin group. For patients undergoing URSL and double-J stent indwelling, postoperative solifenacin use was effective and well-tolerated for the treatment of lower urinary tract symptoms, stent-related body pain and hematuria irrespective of genders. ? Springer-Verlag Berlin Heidelberg 2013.
SDGs
Other Subjects
antibiotic agent; cefalexin; muscarinic receptor blocking agent; paracetamol; polyurethan; solifenacin; muscarinic receptor blocking agent; quinuclidine derivative; solifenacin; tetrahydroisoquinoline derivative; urinary tract agent; quinuclidine derivative; tetrahydroisoquinoline derivative; solifenacin; abdominal pain; adult; article; constipation; controlled study; double J stent; drug efficacy; drug safety; female; headache; hematuria; holmium laser; human; language; lithotripsy; lower urinary tract symptom; major clinical study; male; pain; priority journal; prospective study; questionnaire; scoring system; treatment outcome; ureter stent; Ureteral Symptom Score Questionnaire; ureteroscopic lithotripsy; ureteroscopy; urine retention; xerostomia; adverse effects; aged; controlled clinical trial; hematuria; lithotripsy; middle aged; pain; stent; Ureteral Calculi; Ureteral Obstruction; ureteroscopy; lithotripsy; stent; ureter obstruction; ureter stone; ureteroscopy; abdominal pain; disease severity; Double J stent; drug effect; drug tolerability; flank pain; gender; hematuria; lower urinary tract symptom; medical device complication; urethral pain; urge incontinence; urine retention; Adult; Aged; Female; Hematuria; Humans; Lithotripsy; Male; Middle Aged; Muscarinic Antagonists; Pain; Prospective Studies; Quinuclidines; Solifenacin Succinate; Stents; Tetrahydroisoquinolines; Ureteral Calculi; Ureteral Obstruction; Ureteroscopy; Urological Agents; Adult; Aged; Female; Hematuria; Humans; Lithotripsy; Male; Middle Aged; Muscarinic Antagonists; Pain; Prospective Studies; Quinuclidines; Stents; Tetrahydroisoquinolines; Ureteral Calculi; Ureteral Obstruction; Ureteroscopy; Urological Agents
Type
journal article